Shattuck Labs Inc
STTK3.140USD
-0.010-0.32%
收盤 12/22, 16:00（美東）報價延遲15分鐘
198.30M總市值
虧損本益比TTM
關於 Shattuck Labs Inc 公司
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc簡介
公司代碼STTK
公司名稱Shattuck Labs Inc
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
員工數量44
證券類型Ordinary Share
年結日Oct 09
公司地址500 W. 5Th Street
城市AUSTIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編78701
電話15129004690
網址https://www.shattucklabs.com/
公司代碼STTK
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
Shattuck Labs Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+36.07%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
86.28K
+17.43%
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
81.47K
-8.97%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Hornblower Capital Holdings, LLC
4.57%
其他
58.13%
持股股東
持股股東
佔比
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
Hornblower Capital Holdings, LLC
4.57%
其他
58.13%
股東類型
持股股東
佔比
Hedge Fund
23.34%
Investment Advisor/Hedge Fund
14.04%
Private Equity
9.97%
Corporation
9.51%
Investment Advisor
4.87%
Family Office
2.58%
Research Firm
2.11%
Individual Investor
1.85%
Venture Capital
0.04%
其他
31.69%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
2023Q2
215
27.61M
64.91%
-8.42M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
6.31M
13.16%
+6.31M
--
Sep 02, 2025
Adage Capital Management, L.P.
4.67M
9.76%
--
--
Jun 30, 2025
Redmile Group, LLC
5.54M
11.56%
--
--
Aug 25, 2025
Prosight Capital
6.64M
13.86%
--
--
Jun 30, 2025
Hornblower Capital Holdings, LLC
2.89M
6.04%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
5.45%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.15M
4.48%
-252.36K
-10.51%
Jun 30, 2025
683 Capital Management LLC
1.09M
2.29%
+45.00K
+4.29%
Jun 30, 2025
The Clark Estates Inc.
1.48M
3.08%
--
--
Jun 30, 2025
Pinnacle Associates Ltd.
1.36M
2.85%
+64.00K
+4.92%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
查看更多
Texas Capital Texas Equity Index ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Texas Capital Texas Small Cap Equity Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Shattuck Labs Inc的前五大股東是誰？
Shattuck Labs Inc的前五大股東如下：
OrbiMed Advisors, LLC持有股份：6.31M佔總股份比例：13.16%。
Adage Capital Management, L.P.持有股份：4.67M佔總股份比例：9.76%。
Redmile Group, LLC持有股份：5.54M佔總股份比例：11.56%。
Prosight Capital持有股份：6.64M佔總股份比例：13.86%。
Hornblower Capital Holdings, LLC持有股份：2.89M佔總股份比例：6.04%。
OrbiMed Advisors, LLC持有股份：6.31M佔總股份比例：13.16%。
Adage Capital Management, L.P.持有股份：4.67M佔總股份比例：9.76%。
Redmile Group, LLC持有股份：5.54M佔總股份比例：11.56%。
Prosight Capital持有股份：6.64M佔總股份比例：13.86%。
Hornblower Capital Holdings, LLC持有股份：2.89M佔總股份比例：6.04%。
Shattuck Labs Inc的前三大股東類型是什麼？
Shattuck Labs Inc 的前三大股東類型分別是：
OrbiMed Advisors, LLC
Adage Capital Management, L.P.
Redmile Group, LLC
OrbiMed Advisors, LLC
Adage Capital Management, L.P.
Redmile Group, LLC
有多少機構持有Shattuck Labs Inc(STTK)的股份？
截至2025Q3，共有179家機構持有Shattuck Labs Inc的股份，合計持有的股份價值約為32.72M，占公司總股份的51.71% 。與2025Q2相比，機構持股有所增加，增幅為-22.04%。
哪個業務部門對Shattuck Labs Inc的收入貢獻最大？
在--，--業務部門對Shattuck Labs Inc的收入貢獻最大，創收--，占總收入的--% 。
